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Lung cancer is the primary cause of cancer death. The cure rates
have remained low with only 10% of patients cured of this disease.
According to Landis et al (1998) the estimated annual incidence of,
and mortality from, lung cancer in the United States in 1998 were
171 500 and 160 100, respectively. The low cure rate is due to a
combination of difficulty in detecting early stage disease and low
cure rate for advanced disease. Mountain (1997) analysed the end
results of 5230 patients treated for primary lung cancer. The results
showed that stage I A cancer (TIN0M0: tumour with the greatest
dimension ≤ 30 mm, no nodal involvement or distant metastases)
represented 13% of the total population and had a 5-year survival
rate of 61%. However, the majority of patients in that study had
more advanced cancers with a more dismal outcome. Surgical treat-
ment is expected to be associated with a fairly high 5-year survival
rate for small lung cancers <20 mm without nodal involvement, or
even higher rate for those <15 mm which are often free of nodal
involvement (Sagawa et al, 1990; Oda et al, 1998). Although this is
a difficult goal to achieve by conventional chest radiography, as
was noted by Sone et al (2000), it is rather attainable using low-
dose computed tomography (CT), as has been shown by Kaneko et
al (1996), Sone et al (1998) and Henschke et al (1999). 
We report here the results of annual repeat screenings for lung
cancer using low-dose CT, with a particular focus on the performance
of low-dose CT and characteristics of the detected lung cancers. 
SUBJECTS AND METHODS 
Background 
We conducted a population-based lung cancer screening trial 
from 1996 through 1998 as part of a protocol designed by
Telecommunications Advancement Organisation (TAO) of Japan,
Matsumoto Research Centre, as has been previously described by
Sone et al (1998). The programme was limited to a 5-year period
(1995–1999), which precluded long-term follow-up necessary to
determine the final clinical outcome of the patients found in this
screening. Further it was estimated that we could manage nearly
5000 to 10 000 participants with our mobile screening CT system
in use. Under these limited conditions on the sample size and study
duration, we could not aim to examine the possible benefit of
screening for lung cancer based on a reduction in lung cancer
mortality, we aimed to know among the general population the
frequency of low-dose CT detected suspicious nodules, the results
of work-up examinations together with the frequency of lung
cancers among low-dose CT detected suspicious nodules, and
characteristics of cancers found in the screening. While, according
to Henschke et al (1994), in order to know the efficacy of
screening for lung cancer with CT, we need to examine the three
questions in a given type of the screenee: (1) probability of CT-
detected small solitary pulmonary nodules (SSPN), (2) probability
of malignancy, given detected SSPN, and (3) probability of resec-
tion, given malignancy of the SSPN and cure, given resection of
SSPN; and, in order to determine the first question, which is an
only specific concern to screening, we need to screen some 1000
persons at high-risk for lung cancer, with the expected yield of 100
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of SSPN is required to study the second question, the prevalence
of malignancy among the detected SSPNs, by getting an appre-
ciable number of malignant SSPN, because the prevalence of
malignant SSPN among high-risk population is estimated to be of
the order of 1%. We defined our sample size of 5000 to 10 000,
which was fairly larger than that indicated by Henschke et al,
because we aimed to conduct our trial of CT screening for lung
cancer using CT among the general population, which included
never-smoked inhabitants in this rural area in Japan. In our study,
inhabitants of 29 local municipalities in the Nagano Prefecture,
Japan, who were 40 years of age or older were specifically
requested in 1996 to volunteer for this programme. The annual
mortality rate due to lung cancer in the same region was 37.3 per
100 000 population in 1998. Therefore, it was expected in our trial
at least nearly 100 SSPNs be detected at each annual screening to
undergo work-up examination, which would permit us to estimate
the probability of CT-detected SSPN. Although we expected to
encounter at least several cases with lung cancer among the total
5000 to 10 000 participants, we were not sure about the expected
number of cancer cases because no information on this aspect was
available. All subjects gave informed consent to receive base line
and annual repeat CT scans of the thorax. 
Subjects 
The material of this study comprised a total of 13 786 CT examina-
tions, including 5483 initial CT scans in 1996, 4425 first-year repeat
CT scans in 1997 and 3878 second-year repeat CT scans in 1998
(Table 1). We recommended that all participants receive the initial
and two annual repeat screenings, however 1058 did not undergo
the first annual repeat screening, which was conducted 11–13
months after the 1996 initial screening; these included 34 who had
been found to have highly suspicious lung lesions at the initial
screening and had undergone surgery (29) or were under follow-up
observations (5), 113 who were followed up for probably benign
lesions, and 911 who did not receive it for reasons of their own. 
Among the total of 3878 subjects who received the second
repeat CT scans in 1998, 3522 received the 3 screenings from
1996 through 1998, and 356 received the screening in 1996 but did
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Table 1 Subjects of annual screening by low-dose CT from 1996 to 1998 
Initial screen Annual repeat screening Total 
(1996) (1997) (1998) (1996–98) 
Participants 5483 4425 3878 13 786 
(Women / Men) 
Gender 2412 / 2971 2053 / 2373 1816 / 2062 6381 / 7405 
Mean age(years) 64 66 63 65 
Age of never-smokers (Women / Men) 
40–44 (years in age) 87 72 60 219 
(76 / 11) (59 / 13) (48 / 12) (183 / 36) 
45–49 151 121 104 376 
(122 / 29) (101 / 20) (87 / 17) (310 / 66) 
50–54 323 276 226 825 
(265 / 58) (232 / 44) (196 / 30) (693 / 132) 
55–59 448 373 315 1136 
(375 / 73) (308 / 65) (264 / 51) (947 / 189) 
60–64 698 570 519 1787 
(539 / 159) (446 / 124) (407 / 112) (1392 / 395) 
65–69 776 635 580 1991 
(600 / 176) (494 / 141) (448 / 132) (1542 / 449) 
70–74 471 366 320 1157 
(365 / 106) (292 / 74) (253 / 67) (910 / 247) 
Subtotal 2954 2413 2124 7491 
(2342 / 612) (1932 / 481) (1703 / 421) (5977 / 1514) 
Age of smokers (>1 pack-year) (Women / Men) 
40–44 (years in age) 150 116 105 371 
(15 / 135) (13 / 103) (12 / 93) (40 / 331) 
45–49 195 141 122 458 
(17 / 178) (11 / 130) (11 / 111) (39 / 419) 
50–54 266 207 173 646 
(38 / 228) (29 / 178) (25 / 148) (92 / 554) 
55–59 301 222 188 711 
(24 / 277) (16 / 206) (17 / 171) (57 / 654) 
60–64 474 374 340 1188 
(25 / 449) (17 / 357) (13 / 327) (55 / 1133) 
65–69 667 554 486 1707 
(34 / 633) (21 / 533) (24 / 462) (79 / 1628) 
70–74 476 398 340 1214 
(17 / 459) (14 / 384) (11 / 329) (42 / 1172) 
Subtotal 2529 2012 1754 6295 
(170 / 2359) (121 / 1891) (113 / 1641) (404 / 5891)
(Never-smoker / Smoker > 1 pack-year) 
Smoking in total 2954 / 2529 2413 / 2012 2124 / 1754 7491 / 6295 
in women 2342 / 170 1932 / 121 1703 / 113 5977 / 404 
in men 612 / 2359 481 / 1891 421 / 1641 1514 / 5891 not receive it in 1997 for reasons of their own. Consequently,
among the total of 5483 subjects screened in 1996, 3522 were
further screened twice (1997 and 1998), 903 further screened once
in 1997, 356 were further screened only in 1998, and 702 received
no repeat screening. 
Among the total of 13 786 scans, 6381 (46%) were conducted in
women and 7405 (54%) were in men. With respect to smoking
habits, 7491 (54%) were never-smokers, and 6295 (46%) smokers
(>1 pack year, the average number of packs of cigarettes smoked
per day × duration of smoking in years). Among the 6381
examined females, 5977 (94%) were never-smokers, while among
the 7405 examined males, 1514 (20%) were never-smokers 
(Table 1). 
The median age at the initial screening for the screenees was 63
years for women and 64 years for men. The distribution of
screenees according to age and sex was as follows; age, 40–44
years: 223 (2%) women and 367 (3%) men, 45–49 years: 349 (3%)
women and 485 (4%) men, 50–54 years: 785 (6%) women and 686
(5%) men, 55–59 years: 1004 (7%) women and 843 (6%) men,
60–64 years: 1447 (10%) women and 1528 (11%) men, 65–69
years: 1621 (12%) women and 2077 (15%) men, and 70–74 years:
952 (7%) women and 1419 (10%) men (Table 1). 
Methods 
Screening CT scans and interpretation 
All participants underwent a low-dose non-enhanced spiral CT
scan of the thorax in a mobile CT unit (Model CT-W950SR;
Hitachi Medical, Tokyo, Japan) free-of-charge. The scan parame-
ters were 120 kVp, 50 mA in 1996 and 25 mA in 1997 and 1998,
10 mm collimation, 10 mm s–1 table speed, 2 s rotation of the X-
ray tube, and pitch of 2. Images were displayed and interpreted on
two monochrome high-resolution cathode-ray tubes (CRT) at 3
display conditions to adequately examine the lungs, hilar bronchi
and mediastinum (width 1000 HU, level 700 HU; width 1500
HU, level  550 HU; and width 300 HU, level 20 HU, respec-
tively). The chest radiologists interpreted annual repeat CT images
to detect any abnormality, and then comparison interpretations
were done to know the interval changes of the lesion, shown on the
images of the repeat screening and initial screening. Interpretation
of the images was based on commonly used morphologic and
density characteristics and interval changes of the lesion. We
aimed to classify any lesion into one of 7 categories, as follows:
(A) unsatisfactory examination, (B) normal, (C) lung abnormality
of little clinical importance, (D) non-cancerous lung lesion, (Ed)
non-cancerous but suspicious lung lesion, (E) suspicion of lung
cancer, (F) small lung nodule (<3 mm in diameter). The results of
interpretation were conveyed to each participant via health profes-
sionals at each municipality. 
Diagnostic work-up examinations 
A complete diagnostic work-up examination with conventional
chest radiographs (usually only by the frontal radiograph) and
diagnostic CT (including thin-section, high-resolution CT, HRCT)
was recommended for those individuals with CTs classified as
categories Ed, E or F, and most of them underwent work-up
examinations at our hospital. Patients classified as category D
were recommended to undergo work-up examinations at the local
hospitals. In our hospital, diagnostic CT scans were performed
with a state-of-the-art CT scanner (HiSpeed Advantage, GE
Medical Systems, Milwaukee, WI). Contiguous 10 mm sections
for the whole lung and thin section images (1 mm collimation) to
cover the entire nodule in question were taken and interpreted
based on the morphologic and density characteristics and the pres-
ence of growth tendency of the lesion. Magnetic resonance
imaging or transbronchial lung biopsy was also performed, when
necessary. For subjects with indeterminate lesions, serial follow-
up CTs were conducted at 3, 6, 12, 18 and 30 months, and surgery
was recommended when any increase in size or density of the
nodule was noted. The results of the work-up studies were
conveyed to the patient; our explanation included the results of the
initial and annual repeat screening CT images, the corresponding
diagnostic CT images, as well as the interval changes and probable
CT diagnosis of the detected lung lesion. 
Data analysis 
We compared the initial and annual repeat CT screenings for the
proportions of lung nodules detected on screening CT and
surgically confirmed lung cancers among CT detected suspicious
nodules, and the characteristics of the patients with surgically
confirmed lung cancers. Disease staging was determined
histopathologically according to the TNM (tumour, nodal involve-
ment, metastasis) classification system of the American Joint
Committee on Cancer (AJCC) and Union Internationale Contre le
Cancer’s (UICC) in 1996. 
RESULTS 
Frequency of suspicious nodules detected on
screening CTs (Table 2) 
In the initial CT screening in 1996, 5.1% (279/5483) (95% confi-
dence interval (CI), 2.5–7.7) had possible or probable cancer or
indeterminate nodules <3 mm in diameter. In comparison, in the
annual repeat CTs in 1997 and 1998, 3.9% (173/4425, CI, 1.0–6.8)
and 3.5% (136/3878, CI, 0.4–6.7), had suspicious lesions, respec-
tively. A careful comparison between the CTs of the year and the
preceding year(s) helped to reduce the number of patients, who
had stable lesions, to be classified into category Ed, E or F. 
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Table 2 Low-dose CT detected suspicious nodular lesions during 1996 to 1998 
Initial screening Annual repeat screening Total 
(1996) (1997) (1998) (1996–98) 
Number of screenees 5483 (100%) 4425 (100%) 3878 (100%) 13 786 (100%) 
Probable cancer (E) 109 (2.0%) 40 (0.9%) 26 (0.7%) 175 (1.3%) 
Possible cancer (Ed) 61 (1.1%) 131 (3.0%) 110 (2.8%) 302 (2.2%) 
Small nodule, <3 mm (F) 109 (2.0%) 2 (–)  – 111 (0.8%) 
Subtotal (Ed, E and F) 279 (5.1%) 173 (3.9%) 136 (3.5%) 588 (4.3%) 
Probable benign (D) 397 (7.2%) 100 (2.3%) 109 (2.8%) 606 (4.4%) Frequency of lung cancers among suspicious nodules
detected on screening CTs (Table 3) 
Of the 279 participants who had suspicious nodules detected on
1996 screening, 266 (94%) underwent further radiographic evalu-
ation. Such tests allowed the classification of 34 cases with highly
suspicious cancer nodules. Among these, 29 underwent surgery,
and 22 were histopathologically confirmed to have lung cancer
(0.40% (CI, 0.23–0.57) of all those screened in 1996, or 7.9% (CI,
4.7–11.1) of 279 suspicious examinations at screening CT), 2 had
atypical adenomatous hyperplasias (AAH), and 5 miscellaneous
non-cancerous lesions. Surgery was postponed in two patients who
had multiple small suspicious nodules found at work-up examina-
tions and remain to date under follow-up observation, with the
intention to perform surgery when any lesion shows a significant
increase in size. 3 patients refused surgery. The diagnosis in the
remaining 232 was non-neoplastic pulmonary lesions. There was
one false negative finding on screening CT, which was detected by
cytologic examination of the sputum, verified by bronchoscopy
and treated by surgery. 
Among 173 examinations with suspicious lesions at the first
annual repeat CT of 1997, 168 (97%) received work-up CT exam-
inations. 32 were diagnosed to have a highly suspicious cancer, 30
were subsequently treated surgically and 25 were confirmed lung
cancer cases (detection rate: 0.56%, CI, 0.34–0.78, of the annual
re-examinations of 4425, or 14.5%, CI, 9.1–19.9, of 173 suspected
cases on repeat screening), 4 had atypical adenomatous hyper-
plasias (AAH), and one had non-cancerous lesion. 
Among 136 CTs with suspicious lesions at the second annual
repeat CT of 1998, 129 (95%) received work-up CT examinations,
16 were later diagnosed to have a highly suspicious cancer, 13
were subsequently treated surgically and 9 had lung cancer (detec-
tion rate: 0.23%, CI, 0.08–0.38, of the annual re-examinations of
3878, or 6.4%, CI, 2.2–10.6 of 136 suspected cases on repeat
screening CT), 3 had atypical adenomatous hyperplasias (AAH),
and one had non-cancerous lesion. 
Sensitivity and specificity of interpretation of screening
CT and work-up examinations 
Further examination of the cases detected in the repeat CT
screening showed that among the 25 patients detected in 1997, 16
were retrospectively visible (as lesion >5 mm in diameter) in
1996; and among the 9 patients detected in 1998, one was visible
in 1996 and 3 were visible in 1997. Therefore, we had 17 false
negative readings, in addition to one negative reading for a cyto-
logically detected cancer, in 1996; and 3 false negative cases and 2
additional negative cases due to error in classification in 1997, for
the surgically confirmed cancer lesions >5 mm in diameter.
Accordingly, the sensitivity was 55% (22/40 = 22 + 17 + 1) in
1996 and 83% (25/30 = 25 + 3 + 2) in 1997. We do not have reli-
able data regarding the number of false negative readings in 1998,
because the third year annual repeat screening in 1999 was limited
to those participants living in the city area. 
As to the specificity of our interpretation of screening CTs, there
were 60 cancer cases in 1996–1998, therefore 13 726 (13 786   60)
negative CT examinations were performed, which were not related to
the surgically verified lung cancer, and we made 13 198 negative
readings (Interpretation Classifications of B, C and D); resulting in a
specificity of 97% (13 198/13 726). The specificity was 95% in 1996,
97% in 1997 and 97% in 1998, respectively (details are omitted here). 
Characteristics of surgically confirmed lung cancers
(Table 4) 
Table 4–1 shows the characteristics of 60 patients with lung cancer
by age, gender, smoking history and visibility of tumours on the
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Table 3 Frequency of lung cancers among low-dose CT-detected suspicious nodules 
Initial screening Annual repeat screening Total 
(1996) (1997) (1998) (1996–98) 
Screenees 5483 4425 3878 13 786 
Work-ups recommended 279 173 136 588 
done 266 168 129 563 
Cancer, highly suspicious 34 32 16 82 
Surgery done 29 30 13 72
(histology)
Cancer 22 25 9 56 
AAH* 2 4 3 9 
Non-ca 5 1 1 7 
Postponed 2 1**, 1 1 5 
Rejected 3 – 25  
Indeterminate – 21 3  
Non-cancerous 232 134 112 478 
False negative(1)# 1 –– 1 
False negative(2)## – 21 3  
False negative(3)### (17) (3) (?) (20 + ?) 
Cancer patients confirmed 23 27 10 60 
CT-detected, surgically confirmed cancers 22 25 9  56 
(per 100 000 population) (401) (565) (232) (406) 
*: atypical adenomatous hyperplasia. **: small cell lung cancer, confirmed by transbronchial biopsy, and chemotherapy was done. (1)#: small cancer of hilar type
detected by sputum cytologic exam. (2)##: cancer detected from the categories other than the suspicious nodules, e.g. E (probable cancer), Ed (possible
cancer) or F (small nodule, <3 mm). (3)###: cancer>5 mm in size, that is retrospectively visible, but was only detected in a screening of the one year later (or,
occasionally two years later). chest radiograph. Of these patients, none was younger than 45
years, 4 cancers (7%) were 45–49 years old, 2 (3%) were 50–54
years old, and the remaining 54 (90%) were 55–74 years old. 
The incidence in females was 0.44% (11/2512) [CI, 0.18–0.70],
which was slightly higher than 0.40% (12/2971) [CI, 0.17–0.63] in
men, in the initial screening, and fewer women with a positive CT
were identified in the repeat screening than men, particularly in the
second repeat screening; 0.22% (4/1816) [CI, 0.01–0.43] in
women vs. 0.29% (6/2062) [CI, 0.06–0.52] in men. 
The proportion of patients with lung cancer in never-smokers
was 0.44% (13/2954) [CI, 0.11–0.67], which was slightly higher
than 0.40% (10/2529) [CI, 0.15–0.65] in smokers, in the initial
screening; and it became slightly lower for never-smokers than for
smokers at repeat CT, particularly in the second repeat screening:
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Table 4–1 Characteristics of 60 patients with CT-screening detected and surgically confirmed lung cancers (excluding AAH*) 
Initial screen Annual repeat screening Total 
(1996) (1997) (1998) (1996–98) 
Participants 5483 4425 3878 13 786 
Cancer detected 23 27 10 60 
Mean age (years) 64 66 63 65 
Age of patients (Female / Male) 
40–44 (years) –– – –  
45–49 1/1 2/–– 3/1 
50–54 1/–– – /1 1/1 
55–59 1/3 –/2 1/– 2/5 
60–64 3/1 2/4 1/3 6/8 
65–69 2/3 4/5 2/1 8/9 
70–74 3/4 4/4 –/1 7/9 
Subtotal by gender 11/12 12/15 4/6 27/33 
Smoking history (Never-smoker / Smoker > 1 pack-year) 
40–44 (years) –– – –  
45–49 1/1 2/–– 3/1 
50–54 1/–– – /1 1/1 
55–59 1/3 –/2 1/– 2/5 
60–64 4/– 4/2 1/2 9/4 
65–69 2/3 4/5 2/1 8/9 
70–74 4/3 4/4 –/2 8/9 
Subtotal by smoking 13/10 14/13 4/6 31/29 
Chest radiograph negative 14(61%) 19(70%) 7(70%)  40(67%) 
*: atypical adenomatous hyperplasia. 
Table 4–2 Characteristics of 60 patients with CT-screening detected and surgically confirmed lung cancers (excluding AAH*) 
Initial screen Annual repeat screening Total 
(1996) (1997) (1998) (1996–98) 
Cancer detected 23 27 10 60 
Tumour size
<10 (mm) 6 10 5 21 
11–15 8 12 3 23 
16–20 7 5 1 13 
21–47 2 – 13  
Mean/median 15.1/13.5 12.1/12.0 12.0/10.3 13.4/12.5 
Stage(pathologic) 
1A 21 24 8 53 
1B 2 –– 2 
2A ––11  
2B – 1 – 1 
3A – 1 – 1 
3B – 1 – 1 
4 ––11  
Outcome of patients 
Disease free 21 21 10 55 
Death, due to lung cancer 1 1 – 2 
Death, due to other than lung cancer 1 2 – 3 
Histology (never-/smoker) 
Adenoca (BAC**, well differentiated) 16(12/4) 18(12/6) 8(4/4) 42(28/14) 
Adenoca (moderately-, poorly-differ) 3(–/3) 6(2/4)  – 9(2/7) 
Squamous 4(1/3) 1(–/1) 1(–/1) 6(1/5) 
Small cell – 2(–/2) 1(–/1) 3(–/3) 
*: atypical adenomatous hyperplasia. 
**: bronchioloalveolar cell carcinoma. 0.19% (4/2124) [CI, 0.01–0.37] in never-smokers vs. 0.34%
(6/1754) [CI, 0.07–0.61] in smokers. 
Two thirds (67%, 40/60 cases) of cancers detected on the low-
dose CT were invisible by a retrospective interpretation study on
the chest radiograph. 
Anatomically, 41 (68%) lesions were detected in the right lung,
and 19 (32%) in the left lung. The most common location of lung
cancer was the right upper lobe (22 lesions, 37%), followed by
right lower lobe (15 lesions, 25%), left lower lobe (11 lesions,
18%), left upper lobe (8 lesions, 13%) and right middle lobe (4
lesions, 7%). 
Table 4–2 shows the characteristics of 60 patients with surgi-
cally verified lung cancer by size, stage, outcome and histology.
The diameter of the tumours measured at diagnostic CT ranged
from 4 to 47 mm (mean, 13.4 mm). Specifically, 44 (73%) measur-
ed less than 15 mm; 13 (22%) measured 16–20 mm; and 3 (5%)
were >21 mm in diameter. 53 patients (88% (78.2–97.8)) were
classified as AJCC Stage 1A (postsurgical staging). Postoperative
follow-up (duration: 1.2–3.7 years) of the 60 patients showed 
2 deaths due to lung cancer and 3 deaths due to causes unrela-
ted to lung cancer. The present status of the remaining 55 
patients verified individually within the last 2 months is still
disease-free. 
The most frequent cell type was adenocarcinoma; 51 (85%)
were adenocarcinomas, 6 (10%) squamous cell carcinomas and
3 (5%) small cell carcinomas. Histologic type of cancer was
different between never-smokers and smokers. The proportion of
patients with bronchioloalveolar cell carcinoma (BAC) or well-
differentiated adenocarcinoma in never-smokers was 90% (28/
31 patients), which was markedly higher than 48% (14/29)
in smokers. There was a close association between absence
of smoking history and histologic diagnosis of BAC or well-
differentiated adenocarcinoma (χ 2 test of association, P < 0.001). 
DISCUSSION 
The present report is based on the extended observations
performed on two additional annual repeat CT screening pro-
grammes, following the initial results obtained in 1996 (12). Our
study indicates that low-dose CT is an excellent imaging test for
early detection of lung cancers measuring approximately 5 to 20
mm in size. It allowed detection of a large number of surgically
confirmed cancer cases (56/13 786 CTs), representing a detection
rate of 0.41%, or 406 per 100 000 subjects, which was nearly 11
times as high as the annual mortality rate from lung cancer (37.3
per 100 000) in this country area of Japan. A report released by the
Japanese Research Committee of Studies on Evaluation of
Effectiveness of Cancer Screening (Japanese publication, 1998)
indicated that in 1995 nearly 6 700 000 Japanese of at least 40
years of age and heavy smoking high-risk group were screened
through standard mass screening using chest radiograph and
sputum cytologic examination. Among these, work-up examina-
tions were required on nearly 170 000 subjects (2.5%), and 3144
(1.9%) were subsequently diagnosed with lung cancer (i.e., a
detection rate of nearly 0.05% among all screenees). The results of
our screening programme using low-dose CT differed in several
aspects from the above study. (i) The detection rate of surgically
verified patients with lung cancer was 0.41% (56/13 786); nearly 8
times the rate of the above programme using standard mass
screening. (ii) The rate of work-up examination in our study was
4.3% (588/13 786), which was slightly higher than 2.5% with
standard mass screening. (iii) The rate of identification of lung
cancer among those who underwent work-up examinations due to
suspected lesions to indeterminate abnormality was 10% (56/563),
which was markedly higher than 1.9% in standard mass screening.
(iv) Finally, our analysis showed that the proportion of cases with
stage IA malignancy among cancers detected by CT screening was
approximately 88% (53/60), which was markedly higher than
those reported for stage I from Japan and USA, e.g. 51% (103/206)
by Soda et al (1993) and 63% (44/70) by Flehinger et al (1999). 
Kaneko et al (1996) reported an overall cancer detection rate of
0.43% in CT examinations conducted on men aged 50 years or
older who were heavy smokers, >20 pack-year, and 93% of these
cancers were stage I. Henschke et al (1999) conducted baseline
low-dose CT on 1000 symptom-free volunteers, aged 60 years or
more, with smoking habit of at least 10 cigarette pack-years. They
were able to detect solitary non-calcified nodules in 23% of the
subjects, and 12% of these were later confirmed to be malignant.
The rate (12%) of malignancy among CT detected nodules was
similar to 10% found in our study. 
Many small cancers were detected in the initial CT screening in
1996, however, more cases were detected in the first annual repeat
CT screening in 1997. This was probably due to improved inter-
pretation gained after the first year. This was possible firstly by
learning and experience gained by the radiologists with respect to
characterization of small lung cancers, and secondly by the com-
parison interpretation system devised for interpreting repeat CT
images. In our system, the new and previous CT images were
displayed side by side on two CRT monitors, which enhanced the
detection of trivial changes in the repeat CT image. 
As to the characteristics of patients identified, we found as
many cases of lung cancer in women as in men in the initial
screening; the majority of women in this study were never-
smokers and had mostly bronchioloalveolar carcinoma, BAC, or
well differentiated adenocarcinoma, but the proportion of these
histological types decreased in the repeat screening. This observa-
tion suggests the presence of a relatively large number of slowly
growing cancers among the prevalence cases, particularly among
never-smokers, and that never-smokers should be included in any
screening programme, at least in the initial screening. However,
we found fewer cases in never-smokers in the repeat screening;
this was particularly evident in the third year, when the incidence
cases appeared to form a large proportion of identified cancers,
which tended to accompany small cell lung carcinoma, squamous
cell carcinoma, and moderately to poorly differentiated adenocar-
cinomas. Because this group of cancers may grow rapidly,
smokers should be screened at least once a year. On the contrary,
although persons who are older than 55 years should be advised to
receive CT screening in order to identify the majority of lung
cancers at an early stage, never-smokers may better undergo it 
less frequently than smokers, probably once every 3 to 4 years.
However, the appropriate frequency of CT screening for never-
smokers should be determined in a larger data, which could be
collected, for example, through multi-institutional co-operative
studies. 
At the time of preparation of this report, the mortality rates due
to lung cancer among diagnosed and surgically treated (i.e., histo-
logically confirmed) patients in this study are 4% (1/23) for the
initial CT and 4% (1/27) for the first annual repeat CT. However, a
longer follow-up study is necessary before any firm evaluation
could be made of the outcome of small lung cancers detected in
this study. 
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lung cancers were limited to 56 cases (10%) of 588 suspicious
lesions; this indicates that various types of pulmonary nodules,
mostly non-cancerous, may be detected on low-dose screening CT
and classified as suspicious lesions. Therefore, there is a real need
for the development of an effective strategy for a correct diagnosis
of malignant tumours among suspicious lesions found at
screening, to allow proper management and selection of appro-
priate treatment with little delay in cases with lung cancer. 
Although CT mass screening for lung cancer appears very
promising for the detection of lung cancer mostly at the surgically
curable stage, a careful evaluation of the benefits–risks and cost-
effectiveness issues is important. According to Nishizawa et al
(1996), the effective dose using low-dose CT scan of the chest is
3.6 mSv and the surface dose is 7.6 mGy, when CT scans are
performed with a tube current set at 50 mA. Their risks–benefits
analysis indicated that the benefits of annual CT screening for lung
cancer outweigh the risk in men aged 40 years and women aged 45
years. 
The economic aspects of screening programmes have been fully
discussed by Eddy (1981). Our present programme did not provide
sufficient data to allow a proper evaluation of the economic
aspects of cancer screening. However, we tentatively calculated
the cost of screening by CT per person to be at $50 (5000 Japanese
yen), based on our 3-year CT screening programme (Asakura et al,
Japanese publication, 1999). This was determined by taking into
account the annual costs of capital equipment and maintenance
costs of the mobile CT scanner, digital image display/archive unit,
and reporting system, with depreciation time estimated at 5 years,
in addition to labour costs, and the total of workdays estimated at
150 days per year and 100 participants tested a day. However, it is
hoped that the cost of each test is reduced by the development of
more economical and efficient systems designed mainly for
screening chest diseases. 
Asakura et al (Japanese publication, 1999) examined further the
cost per person year saved, as is partly shown in Table 5–1. It costs
more to save a person year of younger subjects, particularly in
women, and it costs, for example, approximately $21296 for
women and $8148 for men, respectively, to save a person year of
55–59 year-old subjects, when we compute the cost on the
assumption that the detection rate by CT is the same as incidence
rates and the other relevant data could be based on those obtained
at our first 3 years annual low-dose CT screening for lung cancer.
However, in reality, as is shown in Table 5–2, the detection rate for
lung cancers in our screening by CT was much higher than the
annual incidence rate; 10 to 15 times higher in female never-
smokers and 2 to 15 times higher in male smokers, compared to
the annual mortality rates. Consequently, we could expect to save a
person year at a much lower cost by CT screening, at least in the
initial screening. For example, the estimated costs could be
approximately at $2290 ($21296/9.3 (= 211 of CT screening
detected cases/22.6 of age specific mortality rate)) for women and
$728 [$8148/11.2 (=765/68.6) for men, respectively, to save a
person year of the 55–59 year-old subject by CT screening. 
The limitations of the present study include the small number of
cases detected with lung cancers and a limited follow-up period of
screening detected cancer patients to determine survival rates.
These limits do not allow accurate definition of the optimal size of
lung cancer to be detected, necessary for a favourable prognosis,
which consequently limits determination of the appropriate
frequency of CT screening, definition of subjects to be screened,
and work-up examinations for patients with a positive screening
CT scan. 
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Table 5–1 Annual mortality rates by lung cancer by age, and cost to gain a
person year by screening 
Age (year) Annual mortality rates  Cost ($) per person year 
by lung cancer/100 000  gained
Japanese in 1990
Female Male Female Male 
40–44 4.1 8.3 82 407 46 300 
45–49 8.6 18.1 43 519 24 074 
50–54 13.1 28.9 32 407 17 593 
55–59 22.6 68.6 21 296 8148 
60–64 31.3 140.4 17 592 4352 
65–69 53 242.2 12 037 2685 
70–74 83.4 347.2 9259 1944 
Table 5–2 Detection of lung cancer by low-dose CT 
Age (year) Detection rates of lung cancer per 100 000 by CT
screening in 1996–98 (Number of cancers/Number of
participants) 
Never-smoker Smoker 
Female Male F M 
40–44 ––– –  
(–/183) (–/36) (–/40) (–/331) 
45–49 968 –– 239 
(3/310) (–/66) (–/39) (1/419) 
50–54 144 –– 181 
(1/693) (–/132) (–/92) (1/554) 
55–59 211 –– 765 
(2/947) (–/189) (–/57) (5/654) 
60–64 431 759 – 353 
(6/1392) (3/395) (–/55) (4/1133) 
65–69 519 –– 553 
(8/1542) (–/449) (–/79) (9/1628) 
70–74 769 405 – 768 
(7/910) (1/247) (–/42) (9/1172) 
Subtotal 418 264 – 492 
(27/5977) (4/1514) (–/404) (29/5891) 
Subtotal 414 461 
(31/7491) (29/6295) 
Total 435(60/13 786) REFERENCES 
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